Advances in regenerative therapy: A review of the literature and future directions
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
There is enormous global anticipation for stem cell-based therapies that are safe and effective. Numerous pre-clinical studies present encouraging results on the therapeutic potential of different cell types including tissue derived stem cells. Emerging evidences in different fields of research suggest several cell types are safe, whereas their therapeutic application and effectiveness remain challenged. Multiple factors that influence treatment outcomes are proposed including immunocompatibility and potency, owing to variations in tissue origin, ex-vivo methodologies for preparation and handling of the cells. This communication gives an overview of literature data on the different types of cells that are potentially promising for regenerative therapy. As a case in point, the recent trends in research and development of the mesenchymal stem cells (MSCs) for cell therapy are considered in detail. MSCs can be isolated from a variety of tissues and organs in the human body including bone marrow, adipose, synovium, and perinatal tissues. However, MSC products from the different tissue sources exhibit unique or varied levels of regenerative abilities. The review finally focuses on adipose tissue-derived MSCs (ASCs), with the unique properties such as easier accessibility and abundance, excellent proliferation and differentiation capacities, low immunogenicity, immunomodulatory and many other trophic properties. The suitability and application of the ASCs, and strategies to improve the innate regenerative capacities of stem cells in general are highlighted among others.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310 · cited 4×
“The Nobel laureate Yamanaka and his group were the first to successfully reprogram mouse embryonic fibroblast cells in 2006 [29], a year later human skin fibroblast derived iPS cells were reported [31,48,50], prior to the use of peripheral blood mononuclear cells as a tissue source [49].”
BackgroundInfluentialLanger, R., & Vacanti, J. P. (1993) · Science · doi:10.1126/science.8493529 · Cited by 9,893
Multilineage Cells from Human Adipose Tissue: Implications for Cell-Based Therapies
Zuk, P. A., Zhu, M., Mizuno, H., Huang, J., Futrell, J. W., Katz, A. J., Benhaim, P., Lorenz, H. P., & Hedrick, M. H. (2001) · Tissue Engineering · doi:10.1089/107632701300062859 · Cited by 7,956 · cited 6×
“adherent and culture expanded cell population containing both adipose derived stromal cells (ADSCs) and MSCs [8].”
BackgroundMethodInfluentialLutolf, M. P., & Hubbell, J. A. (2005) · Nature Biotechnology · doi:10.1038/nbt1055 · Cited by 4,551
Kern, S., Eichler, H., Stoeve, J., Klüter, H., & Bieback, K. (2006) · STEM CELLS · doi:10.1634/stemcells.2005-0342 · Cited by 3,370
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
Mesenchymal stem cells as trophic mediators
Caplan, A. I., & Dennis, J. E. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20886 · Cited by 2,992
Adipose-derived stem cells for regenerative medicine
Gimble, J. M., Katz, A. J., & Bunnell, B. A. (2007) · Circulation Research · doi:10.1161/01.res.0000265074.83288.09 · Cited by 2,332 · cited 1×
“Liposuction is a less sophisticated procedure with minor adverse effects and ethical restrictions (Table 2) [114,140].”
BackgroundBourin, P., Bunnell, B. A., Casteilla, L., Dominici, M., Katz, A. J., March, K. L., Redl, H., Rubin, J. P., Yoshimura, K., & Gimble, J. M. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.02.006 · Cited by 1,890 · cited 5×
“Additionally, surface markers CD13, CD29, and CD44 should be constitutively expressed by >80% of ASCs, while CD31, CD45, and CD235a, which are primarily negative markers, should be expressed by less than 2% of cells [94].”
BackgroundMethodInfluentialMesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities
Galipeau, J., & Sensébé, L. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.05.004 · Cited by 1,819 · cited 6×
“Suggested factors significantly contributing to the dissonance include differences in cell preparation, potency, and functionality amongMSCs tissue sources, culture methods, and expansion levels, and variations in cell handling including thawing, route of delivery, and dosing [35].”
BackgroundInfluentialInduced pluripotent stem cell technology: a decade of progress.
Shi, Y., Inoue, H., Wu, J. C., & Yamanaka, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.245 · Cited by 1,525 · cited 1×
“Also, the iPS cell technology has incorporated innovative technologies such as gene editing and threedimensional organoids, which have greatly boosted efforts in disease modeling, drug discovery, and cell therapy [53,54].”
BackgroundMesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine
Vizoso, F., Eiro, N., Cid, S., Schneider, J., & Perez-Fernandez, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091852 · Cited by 1,363
Isolation of Mesenchymal Stem Cells of Fetal or Maternal Origin from Human Placenta
in 't Anker, P. S., Scherjon, S. A., Kleijburg‐van der Keur, C., de Groot‐Swings, G. M. J. S., Claas, F. H. J., Fibbe, W. E., & Kanhai, H. H. H. (2004) · STEM CELLS · doi:10.1634/stemcells.2004-0058 · Cited by 1,189 · cited 1×
“Some studies consider the harvesting process relatively harmless, and do not clearly distinguish fetal and adult sources given that sometimes the origin can be both maternal and fetal [16,18,72,73].”
BackgroundThe tumorigenicity of human embryonic and induced pluripotent stem cells
Ben-David, U., & Benvenisty, N. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3034 · Cited by 889
Spaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807
Generation of induced pluripotent stem cells from human blood
Loh, Y.-H., Agarwal, S., Park, I.-H., Urbach, A., Huo, H., Heffner, G. C., Kim, K., Miller, J. D., Ng, K., & Daley, G. Q. (2009) · Blood · doi:10.1182/blood-2009-02-204800 · Cited by 626
Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations
Merkle, F. T., Ghosh, S., Kamitaki, N., Mitchell, J., Avior, Y., Mello, C., Kashin, S., Mekhoubad, S., Ilic, D., Charlton, M., et al. (2017) · Nature · doi:10.1038/nature22312 · Cited by 506
Moll, G., Ankrum, J. A., Kamhieh-Milz, J., Bieback, K., Ringdén, O., Volk, H.-D., Geissler, S., & Reinke, P. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.12.006 · Cited by 440 · cited 1×
“Some of the initial reports on the use of human placenta-derived MSC-like cells in a Phase 1b/2a study in Crohn's disease highlighted the occurrence of venous thrombotic events in two patients [77], and posited tissue factor (TF) expression by the clinical-grade therapeutic MSCs as a possible cause [78,79].”
BackgroundProgress in tissue engineering
Khademhosseini, A., Vacanti, J. P., & Langer, R. (2009) · Scientific American · doi:10.1038/scientificamerican0509-64 · Cited by 403
Sekine, H., Shimizu, T., Hobo, K., Sekiya, S., Yang, J., Yamato, M., Kurosawa, H., Kobayashi, E., & Okano, T. (2008) · Circulation · doi:10.1161/circulationaha.107.757286 · Cited by 373 · cited 1×
“For example, endothelial cells can be combined with different tissue cell types to promote angiogenesis of cardiac tissue [277], skin [271] or oral mucosa [278] repair.”
BackgroundTissue-resident stem cells promote breast cancer growth and metastasis
Muehlberg, F. L., Song, Y.-H., Krohn, A., Pinilla, S. P., Droll, L. H., Leng, X., Seidensticker, M., Ricke, J., Altman, A. M., Devarajan, E., et al. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp036 · Cited by 330
Hong, P., Yang, H., Wu, Y., Li, K., & Tang, Z. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1358-y · Cited by 269
CD106 Identifies a Subpopulation of Mesenchymal Stem Cells with Unique Immunomodulatory Properties
Yang, Z. X., Han, Z.-B., Ji, Y. R., Wang, Y. W., Liang, L., Chi, Y., Yang, S. G., Li, L. N., Luo, W. F., Li, J. P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059354 · Cited by 225
Mesenchymal markers on human adipose stem/progenitor cells
Zimmerlin, L., Donnenberg, V. S., Rubin, J. P., & Donnenberg, A. D. (2013) · Cytometry Part A · doi:10.1002/cyto.a.22227 · Cited by 225
Overview: An iPS cell stock at CiRA
Umekage, M., Sato, Y., & Takasu, N. (2019) · Inflammation and Regeneration · doi:10.1186/s41232-019-0106-0 · Cited by 122
Kuci, Z., Bonig, H., Kreyenberg, H., Bunos, M., Jauch, A., Janssen, J. W. G., kifi, M., Michel, K., Eising, B., Lucchini, G., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.140368 · Cited by 118
Blázquez-Prunera, A., Díez, J. M., Gajardo, R., & Grancha, S. (2017) · Stem Cell Research & Therapy · doi:10.1186/s13287-017-0552-z · Cited by 79
Azuma, K., & Yamanaka, S. (2016) · Regenerative Therapy · doi:10.1016/j.reth.2016.01.009 · Cited by 63
Cited by
Cell Therapy: Types, Regulation, and Clinical Benefits
El-Kadiry, A. E.-H., Rafei, M., & Shammaa, R. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.756029 · Cited by 256
“or ADSCs), which can constitute up to 10% of its fraction depending on the processing technique, usually involving serial straining and centrifugation of SVF and cell culture in growth media (189).”
BackgroundCarmona-Luque, M., Ballesteros-Ribelles, A., Millán-López, A., Blanco, A., Nogueras, S., & Herrera, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13092480 · Cited by 6
“…known that the MSC-derived secretome can be affected by MSC culture conditions, such as the source of the cells, the number of culture passages carried out before their applications, the culture medium and supplementary factors, and modifications in cell handling such as freezing or thawing [36].”
Background
Metadata
- Authors
- Ntege, E. H., Sunami, H., & Shimizu, Y.
- Venue
- Regenerative Therapy
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 14
- Pages
- 136-153
- ISSN
- 2352-3204 (ISSN-L)
- OpenAlex
- W3008764614
- Cited by
- 194
- References
- 30
- FWCI
- 11.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.